Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin

Journal of Medical Virology

Volumn 84, Issue 3, 2012, Pages 438-444

  Hayashi, Kazuhiko ^a   Katano, Yoshiaki ^a   Kuzuya, Teiji ^a   Tachi, Yoshihiko ^a   Honda, Takashi ^a   Ishigami, Masatoshi ^a   Itoh, Akihiro ^a   Hirooka, Yoshiki ^a   Ishikawa, Tetsuya ^a   Nakano, Isao ^a   Urano, Fumihiro ^b   Yoshioka, Kentaro ^c   Toyoda, Hidenori ^d   Kumada, Takashi ^d   Goto, Hidemi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Genotype 1a; Hepatitis C virus; IL 28B; Interferon; NS5A

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 28B; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

5' UNTRANSLATED REGION; ADULT; ARTICLE; CLINICAL EVALUATION; DNA POLYMORPHISM; FEMALE; GENE MUTATION; GENOTYPE; HEMOPHILIA; HEPATITIS C; HEPATITIS VIRUS; HUMAN; INFECTION RATE; INTERFERON SENSITIVITY DETERMINING REGION; JAPAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; RNA EXTRACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROGNOSIS; RECOMBINANT PROTEINS; RIBAVIRIN; SEQUENCE ALIGNMENT; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1;

EID: 84855898279     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23207     Document Type: Article

References (42)

1. Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2005. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48: 372-380.
2. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H. 2007. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. Hepatology 46: 1357-1364.
3. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. 2009. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. J Med Virol 81: 1032-1039.
4. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H. 2010. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52: 421-429.
5. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y, Kumada H. 2011. Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology (in press).
6. Alestig E, Arnholm B, Eilard A, Lagging M, Nilsson S, Norkrans G, Wahlberg T, Wejstål R, Westin J, Lindh M. 2011. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection. BMC Infect Dis 12: 124.
7. Dal Pero F, Tang KH, Gerotto M, Bortoletto G, Paulon E, Herrmann E, Zeuzem S, Alberti A, Naoumov NV. 2007. Impact of NS5A sequences of hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon-alpha 2a plus ribavirin. J Infect Dis 196: 998-1005.
8. Enomoto N, Takada A, Nakao T, Date T. 1990. There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Commun 170: 1021-1025.
9. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. 1996. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334: 77-81.
10. Fujimura Y, Ishimoto S, Shimoyama T, Narita N, Kuze Y, Yoshioka A, Fukui H, Tanaka T, Tsuda F, Okamoto H, Miyakawa Y, Mayumi M. 1996. Genotypes and multiple infections with hepatitis C virus in patients with haemophilia A in Japan. J Viral Hepat 3: 79-84.
11. Gale M, Jr., Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG. 1998. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation. Mol Cell Biol 18: 5208-5218.
12. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
13. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. 2009. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49: 1335-1374.
14. Hayashi K, Fukuda Y, Nakano I, Katano Y, Toyoda H, Yokozaki S, Hayakawa T, Morita K, Nishimura D, Kato K, Urano F, Takamatsu J. 2003. Prevalence and characterization of hepatitis C virus genotype 4 in Japanese hepatitis C carriers. Hepatol Res 25: 409-414.
15. Hayashi K, Katano Y, Takeda Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Nakano I, Yano M, Goto H, Yoshioka K, Toyoda H, Kumada T. 2007. Comparison of hepatitis B virus subgenotypes in patients with acute and chronic hepatitis B and absence of lamivudine-resistant strains in acute hepatitis B in Japan. J Med Virol 79: 366-373.
16. Hayashi K, Katano Y, Ishigami M, Itoh A, Hirooka Y, Nakano I, Urano F, Yoshioka K, Toyoda H, Kumada T, Goto H. 2011a. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy. J Viral Hepat 18: 280-286.
17. Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H. 2011b. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy. Liver Int 9: 1359-1365.
18. Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K. 2011. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 60: 261-267.
19. Herion D, Hoofnagle JH. 1997. The interferon sensitivity determining region: All hepatitis C virus isolates are not the same. Hepatolgy 25: 769-770.
20. Hofgärtner WT, Polyak SJ, Sullivan DG, Carithers RL, Jr., Gretch DR. 1997. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b. J Med Virol 53: 118-126.
21. Kumada H, Okanoue T, Onji M, Moriwaki H, Izumi N, Tanaka E, Chayama K, Sakisaka S, Takehara T, Oketani M, Suzuki F, Toyota J, Nomura H, Yoshioka K, Seike M, Yotsuyanagi H, Ueno Y, The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labour and Welfare of Japan. 2010. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 40: 8-13.
22. Kumthip K, Pantip C, Chusri P, Thongsawat S, O'Brien A, Nelson KE, Maneekarn N. 2011. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. J Viral Hepat 18: e117-e125.
23. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M. 2011. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 54: 439-448.
24. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358: 958-965.
25. Matsuura K, Tanaka Y, Hige S, Yamada G, Murawaki Y, Komatsu M, Kuramitsu T, Kawata S, Tanaka E, Izumi N, Okuse C, Kakumu S, Okanoue T, Hino K, Hiasa Y, Sata M, Maeshiro T, Sugauchi F, Nojiri S, Joh T, Miyakawa Y, Mizokami M. 2009. Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 47: 1476-1483.
26. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580-593.
27. Nakagawa M, Sakamoto N, Ueyama M, Mogushi K, Nagaie S, Itsui Y, Azuma S, Kakinuma S, Tanaka H, Enomoto N, Watanabe M. 2010. Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. J Gastroenterol 45: 656-665.
28. Nakano I, Fukuda Y, Katano Y, Nakano S, Kumada T, Hayakawa T. 1999. Why is the interferon sensitivity-determining region (ISDR) system useful in Japan? J Hepatol 30: 1014-1022.
29. Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, Tanaka E, Onji M, Toyota J, Chayama K, Yoshioka K, Izumi N, Akuta N, Kumada H. 2009. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: A Japanese multi-center study. J Gastroenterol 44: 952-963.
30. Otagiri H, Fukuda Y, Nakano I, Katano Y, Toyoda H, Yokozaki S, Hayashi K, Hayakawa T, Fukuda Y, Kinoshita M, Takamatsu J. 2002. Evaluation of a new assay for hepatitis C virus genotyping and viral load determination in patients with chronic hepatitis C. J Virol Methods 103: 137-143.
31. Pascu M, Martus P, Höhne M, Wiedenmann B, Hopf U, Schreier E, Berg T. 2004. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: A meta-analysis focused on geographical differences. Gut 53: 1345-1351.
32. Sakugawa H, Nakasone H, Kinjo F, Saito A, Keida Y, Kikuchi K, Oyadomari Y, Ishihara M, Nakasone K, Yogi S, Kinjo Y, Taira M. 1997. Clinical features of patients with chronic liver disease associated with hepatitis C virus genotype 1a/I in Okinawa, Japan. J Gastroenterol Hepatol 12: 176-181.
33. Seeff LB. 2002. Natural history of chronic hepatitis C. Hepatology 36: S35-S46.
34. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973.
35. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
36. Tachi Y, Katano Y, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Samejima Y, Goto H. 2010. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver Int 30: 554-559.
37. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
38. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
39. Toyoda H, Kumada T, Tada T, Arakawa T, Hayashi K, Honda T, Katano Y, Goto H. 2010. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load. J Gastroenterol Hepatol 25: 1072-1078.
40. Yahoo N, Sabahi F, Shahzamani K, Malboobi MA, Jabbari H, Sharifi H, Mousavi-Fard SH, Merat S. 2011. Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment. J Med Virol 83: 1332-1337.
41. Yokozaki S, Katano Y, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Goto H. 2011. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness. J Med Virol 83: 1727-1732.
42. Zeuzem S, Lee JH, Roth WK. 1997. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 25: 740-744.